Unione Europea - italiano - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - leucemia, linfocitica, cronica, b-cell - agenti antineoplastici - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - venetoclaxum - compresse rivestite con film - venetoclaxum 10 mg, excipiens pro compresso haze. - chronisch lymphatische leukämie (cll), akute myeloische leukämie (aml) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - venetoclaxum - compresse rivestite con film - venetoclaxum 50 mg, excipiens pro compresso haze. - chronisch lymphatische leukämie (cll), akute myeloische leukämie (aml) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - venetoclaxum - compresse rivestite con film - venetoclaxum 100 mg, excipiens pro compresso haze. - chronisch lymphatische leukämie (cll), akute myeloische leukämie (aml) - synthetika